main menu

About Us

SurgihoneyRO™ is an antimicrobial wound gel, a Class IIb medical device for the management of infected, chronic and acute wounds through to healing.

SurgihoneyRO™ is a unique, patented preparation that delivers Reactive Oxygen® to the wound bed.  It has been proven to be effective against multi drug-resistant microorganisms commonly found in chronic wounds providing a solution in this era of antibiotic resistance.


Matoke® Holdings Medical device division distributes SurgihoneyRO™ through its partner H&R Healthcare Ltd.

H&R Healthcare Ltd are UK distributors of the highest quality medical devices sourced from leading manufacturers throughout the world.  Mike Hoskins, owner and Managing Director states, “SurgihoneyRO™ is an outstanding, disruptive technology that has the potential to transform the antimicrobial market, heal patients more quickly, and reduce antimicrobial prescribing”.

Matoke® Holdings Ltd is developing its patented Reactive Oxygen® technology as novel treatments which are much more than conventional antibiotics through its pharmaceutical division, Matoke® Pharma. With the World Health Organisation predicting that millions may die due to global antimicrobial resistance (AMR), Reactive Oxygen® technology offers a potential solution to the global AMR threat which can help save lives. Matoke® Holdings Ltd is a privately-owned UK- based company, a member of the BioIndustry Association (BIA) and registered Small to Medium-sized Enterprise (SME) with the European Medicines Agency (EMA).


Board Members:

Ian Staples

Non-Executive Director, Founder

Ian Staples has had a distinguished executive career in the retail sector, including Managing Director of Halfords. He made the original discoveries on which Matoke® Holdings Ltd’s Reactive Oxygen® technology is based and has been instrumental in developing and bringing the CE marked medical device, SurgihoneyRO™, to market. His passion and drive has attracted a range of very high quality, committed and determined specialists to the team, which are also helping to bring the pharmaceutical product RO™ 101 to market, which will help transform the lives of patients throughout the world.

Brian McGowan


Brian McGowan is the Chairman of Matoke® Holdings Ltd, bringing a wealth of business experience to drive forward the business’ expansion. Brian co-founded Williams Holdings in 1982, which became one of the most successful companies of the 1980s and 1990s and included businesses such as Crown Paints, Polycell, Cuprinol, Kidde, Chubb, Thorn and Yale. After retiring from Williams in 1993 he became Chairman at House of Fraser plc, Rentokil plc, Umeco plc and Atlantra (previously Catalyst Corporate Finance).

Alan Westwood

Research Director

Alan Westwood is an anti-infective strategic specialist who formerly served as Vice President, Global Strategic Marketing, at Bayer. Alan is overseeing the research and development of RO™ 101 in the pharmaceutical division.

Andy Currie

Non-Executive Director

Andy Currie is a Non-Executive Director of Matoke® Holdings Ltd and is Managing Partner of Atlantra (previously Catalyst Corporate Finance). With a corporate finance career spanning over 25 years, Andy provides particular knowledge and expertise of Human Capital businesses, such as consultancies and professional services firms, and of advising private equity, bank consortia and other complex shareholder structures. An alumnus of Leicester University, Andy qualified as a Chartered Accountant with Price Waterhouse, (now PwC) and had a spell in industry with a listed building services firm prior to the formation of Catalyst in 1998.

Ian Jenkins

Legal Counsel

Ian Jenkins is Matoke® Holdings Ltd’s Legal Counsel, and was the Senior Partner for 13 years of a City firm of solicitors with offices in London, Hong Kong and Shanghai. He also served as a non-executive director of a number of client companies, both public and private.

Dr Matthew Dryden

Chief Clinical Officer

Dr Matthew Dryden is a Clinical Director of Infection at the Hampshire Hospitals Trust, and the Rare and Imported Pathogens Department, Public Health England (PHE) and a senior lecturer at Southampton University Medical School. Recently he was General Secretary of the British Society for Antimicrobial Chemotherapy. His research interests include staphylococcal infection, skin and soft tissue infection, the development of new antibiotics, antibiotic stewardship, and the management of MRSA infections.

Professor Jonathan Cooke

Chief Scientific Officer

Professor Jonathan Cooke was Director of Research and Development and Chief Pharmacist at University Hospital of South Manchester, Honorary Professor, Manchester Pharmacy School, University of Manchester and Visiting Professor, Department of Medicine, Imperial College London. He has a specialist interest in antimicrobial resistance and was a member of the UK Department of Health’s Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI), Chair of the Antimicrobial Stewardship Committee and Advisor to WHO.

Mike Hoskins

Managing Director, Medical Device Division

Mike Hoskins oversees Matoke® Holdings’ medical device division and the Managing Director of H&R Healthcare, which manages the distribution of SurgihoneyRO. He has extensive experience in the medical device industry, having held Board level positions at Smith & Nephew and BSN Medical. He established H&R Healthcare in 2006, a leading distributor of third party wound management products in the UK, which has over 130 employees. Mike is also Chair of Onbone OY, a Finnish medical device manufacturer.

Guy Reynolds

Chief Executive Officer

Guy went to Oxford University, qualified as a solicitor with Linklaters and then spent several years with Credit Suisse in their Equity Corporate Finance Team. Until recently he was CEO of Leaders in Oncology Care a subsidiary of HCA International and CEO of their entire cancer network. He is involved in several medical businesses and brings a wealth of management and execution experience to the team. He is also a non-executive director of VCP Advisors.

Will Wijnberg

Executive Director

Will studied Natural Sciences at Bath University and began his career as a management consultant for Accenture. He worked with a very wide variety of clients including Deutsche Bank, BBC, Thales, and BT, his roles were across strategy, estimation, planning and delivery. More recently he was CEO of a direct to consumer business, The London Sock Company, before joining Guy in the medical world. He brings planning and delivery rigor as well as strong business strategy and management skills.

What is SurgihoneyRO™?

Reactive Oxygen®

Why is it different?

Indications for use

How to apply

Clinical Evidence

Case Studies

Case Studies

Deep traumatic wound that had become critically infected

Dr Jill Brooks

Download PDF »

Critically infected leg amputation site

Dr. Matthew Dryden

Download PDF »

Long term leg ulcer

Dr. Matthew Dryden

Download PDF »

Critically infected leg ulcer

Dr. Matthew Dryden

Download PDF »

Baby with MRSA infected surgical wound

Dr. Matthew Dryden

Download PDF »

Chronic, long term, heavily infected, ischaemic ulcers

Dr. Matthew Dryden

Download PDF »

Clinical Evidence

Reactive Oxygen<sup>®</sup> Made Easy

Reactive Oxygen® Made Easy

Dryden, M. and Stephens, C., Wounds UK, 2018, 14 (5)

A multi-centre clinical evaluation of SurgihoneyRO™ in 114 wounds

Dryden, M., Dickinson, Brooks, J., A., Hudgell, L., Saeed, K. and Cutting, K.F., Journal of Wound Care, 2016, 25 (3)

A multi-centre clinical evaluation of SurgihoneyRO™ in 114 wounds

Using antimicrobial SurgihoneyRO™ to prevent caesarean wound infection

Dryden, M., Goddard, C., Madadi, A., et al., British Journal of Midwifery, 2014, 22 (1)

Using antimicrobial SurgihoneyRO™ to prevent caesarean wound infection

A topical antimicrobial wound gel to treat multi-drug resistant pathogens in wound care

Thomas, H., Davies, L. and Westgate, S.J., Poster, Perfectus biomed, 2018

A topical antimicrobial wound gel to treat multi-drug resistant pathogens in wound care
Treatment of World Health Organisation priority pathogens using an antimicrobial wound gel

Treatment of World Health Organisation priority pathogens using an antimicrobial wound gel

Thomas, H., Davies, L. and Westgate, S.J., Poster, Perfectus biomed, 2018

Bioengineered honey: in vitro antimicrobial activity of a novel topical wound care treatment

Dryden, M., Journal of Global Antimicrobial Resistance & Journal of Antimicrobial Chemotherapy, 2014

Bioengineered honey: in vitro antimicrobial activity of a novel topical wound care treatment

How to apply

SurgihoneyRO™ is applied directly to the wound bed or surgical incision site

To ensure optimum results please follow the following guidelines:

  • Cleanse the wound as per local guidelines
  • Apply 2mm thickness directly to the wound bed. Alternatively, SurgihoneyRO™ can be applied to an inert wound contact or secondary dressing then placed on the wound bed
  • Select an appropriate secondary dressing for exudate level and to maintain moist wound healing environment
  • A tube of SurgihoneyRO™ may be used on a single patient, multiple times, for up to 28 days

It is recommended that SurgihoneyRO™ is applied every 72 hours (3 days) and more frequently in critical wound infections to maximise effect.

  • For critically infected wounds, it is recommended that SurgihoneyRO™ is applied daily then reduce to alternate days, then to every 3 days over the first 2 weeks (subject to individual clinical scenario). If there is no improvement in the wound condition and microbial status use should be reviewed
  • For surgical incision sites, it is recommended to apply SurgihoneyRO™ once immediately after closure to assist healing and as a secondary infection prevention measure

SurgihoneyRO™ may be used under compression bandaging for up to 7 days however potency will decrease after day 3.

With a low therapeutic dose of H202 there are no contraindications associated with long term use and it is non-toxic to healthy tissue. It may be used on children.

Indications for use

SurgihoneyRO™ is indicated for infected, chronic and acute wounds through to wound healing

Chronic wounds including:-

  • Diabetic foot ulcers
  • Pressure ulcers
  • Leg ulcers

Infected wounds

Acute wounds including:-

  • Surgical wounds
  • Traumatic wounds, cuts and abrasions
  • Burns
  • Donor and recipient sites

SurgihoneyRO™ is a safe and effective multi-action product without the drawbacks of other antimicrobial wound dressings. The bioengineering ensures a consistent level of therapeutically active Reactive Oxygen® which aids the antimicrobial activity for up to 3 days.

Why is it different?

When SurgihoneyRO™ comes into contact with moisture, Reactive Oxygen® is instantly released and sustained for over 72 hours1

Medical-grade honey is an established topical treatment for wounds and burns due to its antimicrobial and wound healing promotion activity. It provides rapid autolytic debridement, reduces odour and decreases wound-related pain and bio-burden2. Honey works in a different way to antibiotics – it is hypersomolar, restricting the availability of water to bacteria and dehydrating bacteria by osmosis.

Natural honeys vary hugely in their antimicrobial properties and there is little consistency in antimicrobial effects because there can be no control over nectar source, sugar content and other contaminants in entirely natural products. Many medicinal honeys are based on Manuka honey, which is one of the more antimicrobial natural honeys.

Different mechanisms of action have been suggested for the antimicrobial effects of honey, but the main ones are the high-sugar concentration, H2O2, the 1,2-dicarbonyl compound methylglyoxal (MGO), the cationic antimicrobial peptide bee defensin-1 and the low pH3. Some patients may experience momentary stinging or a drawing sensation when using honey therapies due to its autolytic debriding properties and the drawing of fluids by osmosis away from the wound4.

SurgihoneyRO™ has all the natural healing-inducing, desloughing and tissue regenerative properties of the honey carrier, but it has been bioengineered to deliver precisely controlled level of Reactive Oxygen®.

SurgihoneyRO™ is a fast acting, effective antimicrobial.

SurgihoneyRO™ not only inhibits but also kills microbes at concentrations 10-1000 fold below those that are likely to be achieved in topical treatment. The speed of cidal activity is shown by the time-kill curves to be extremely rapid.4.


Reactive Oxygen®

SurgihoneyRO™ is the first published, antimicrobial wound dressing that has been tested against the 12 priority MDR bacterial strains, and has been shown to be effective against almost all these organisms1

The term reactive oxygen species (ROS) describes highly reactive molecules containing reduced oxygen or oxygen atoms with extra electrons. Members of the ROS family include superoxide anion O2, peroxide O22, hydrogen peroxide H2O2.

ROS are naturally occurring in the body. Basal ROS levels maintain normal cell functioning and homeostasis2, while increased amounts induce a cell-mediated antimicrobial defence response3.

ROS are part of the innate immune response, and play a critical role in wound healing and infection control at the wound site4. They are released within minutes of epithelial injury, signalling rapid recruitment of leukocytes5. ROS directly damage microbes that invade tissues6. In wound healing, ROS are secondary messengers to many immunocytes and non-lymphoid cells, and regulate angiogenesis, haemostasis and tissue repair7.

Reactive Oxygen® is the antimicrobial mechanism for SurgihoneyRO™. In contact with moisture, SurgihoneyRO™ releases Reactive Oxygen®.

In vitro studies have shown that Reactive Oxygen® at close to naturally occurring levels:

  • Stimulates proliferation of human fibroblasts and vascular endothelial cells5,13
  • Stimulates angiogenesis via vascular endothelial growth factor (VEGF) signalling14
  • Promotes keratinocyte cell migration and proliferation15

A controlled and sustained level of H2O2 that is non-harmful and non-toxic to surrounding tissue, is a therapeutic opportunity for wound care. SurgihoneyRO™ does this through the release of Reactive Oxygen®. To find out more on the technology of SurgihoneyRO™ and Reactive Oxygen®, read the Reactive Oxygen Made Easy.

Scientists from the National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, the research arm of the NHS, demonstrated SurgihoneyRO™ is highly effective at tackling a wide variety of bacterial biofilm found in chronic wounds in vitro.

“Given the threat posed by antimicrobial resistance and the ever-increasing need to find new solutions to treat infections, SurgihoneyRO™ has real potential as a new wound care agent to kill bacteria and disrupt biofilm.” – Fenella Halstead, Clinical scientist, National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre.

SurgihoneyRO™ has been successfully used for infection prevention, eradication of MDR bacterial strains and prevention of surgical site infections and intravascular line care in vivo15,16,17.

The Reactive Oxygen® released by SurgihoneyRO™ is a broad-spectrum antimicrobial against wound-relevant MDR bacterial strains and has been shown to prevent and disrupt and eradicate mature biofilm.

SurgihoneyRO™ presents one option against the growing global issue of antimicrobial resistance.



What is SurgihoneyRO™?

SurgihoneyRO™ is a cutting-edge technology, an antimicrobial wound gel utilising bioengineered honey to deliver Reactive Oxygen® (RO™)

SurgihoneyRO™ provides enhanced healing and a powerful antimicrobial action to reduce the microbial load thus removing the barriers to wound healing. Unlike other medical grade honeys, SurgihoneyRO™ has been bioengineered to enhance and precisely control its antimicrobial potency.

  • Kills a wide range of bacteria in vitro1,2,3
  • Prevents biofilm in vitro1
  • Fast acting antimicrobial action2
  • Substantially eradicates mature biofilm in vitro4,5
  • Effective against multi drug-resistant microorganisms commonly found in chronic wounds6
  • Effective debridement
  • Assists the natural wound healing environment and promotes new tissue growth

SurgihoneyRO™ is the only published, proven antimicrobial wound dressing tested against the WHO priority pathogens6.